1207454-85-0

Basic information

• Product Name: (E)-4-(4-chlorobenzylideneamino)isobenzofuran-1(3H)-one
• Synonyms: (E)-4-(4-chlorobenzylideneamino)isobenzofuran-1(3H)-one;4-[(E)-[(4-chlorophenyl)methylene]amino]- 1(3H)-Isobenzofuranone
• CAS NO: 1207454-85-0
• Molecular Formula: C₁₅H₁₀ClNO₂
• Molecular Weight: 271.6984
• Mol File: 1207454-85-0.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-4-(4-chlorobenzylideneamino)isobenzofuran-1(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-(4-chlorobenzylideneamino)isobenzofuran-1(3H)-one(1207454-85-0)
• EPA Substance Registry System: (E)-4-(4-chlorobenzylideneamino)isobenzofuran-1(3H)-one(1207454-85-0)

Safety Data

• Hazardous Substances Data: 1207454-85-0(Hazardous Substances Data)

Usage

Description

(E)-4-(4-chlorobenzylideneamino)isobenzofuran-1(3H)-one, also known as SU6656, is a chemical compound with significant pharmaceutical and medicinal potential. It is recognized as a selective inhibitor of the Src family of tyrosine kinases, which are integral to cell signaling and growth processes. (E)-4-(4-chlorobenzylideneamino)isobenzofuran-1(3H)-one has garnered attention due to its possible applications in various medical fields, including cancer treatment, cell cycle regulation, apoptosis, neurodegenerative diseases, and other conditions associated with abnormal cell growth. As research progresses, SU6656 holds promise as a therapeutic agent for a range of medical conditions.

Uses

Used in Pharmaceutical Industry:
SU6656 is used as a therapeutic agent for its potential role in the treatment of cancer. It targets the Src family of tyrosine kinases, which are often dysregulated in cancer cells, contributing to uncontrolled cell growth and proliferation. By inhibiting these kinases, SU6656 may help in controlling tumor growth and improving patient outcomes.
Used in Research and Development:
In the field of biomedical research, SU6656 is utilized as a research tool to study the role of Src family kinases in cell cycle regulation and apoptosis. Understanding these processes is crucial for developing targeted therapies and identifying potential therapeutic targets for various diseases.
Used in Neurodegenerative Disease Research:
SU6656 is also being investigated for its potential role in neurodegenerative diseases. Since abnormal cell growth and signaling are often implicated in such conditions, the compound's ability to inhibit Src kinases may provide insights into the development of novel treatment strategies.
Used in Drug Development for Abnormal Cell Growth Conditions:
Beyond cancer and neurodegenerative diseases, SU6656 is explored for its potential applications in other medical conditions related to abnormal cell growth. Its inhibitory effects on Src kinases could offer new avenues for therapeutic intervention in a variety of diseases where cell signaling dysregulation plays a significant role.

Upstream product

• 65399-18-0 4-nitrophthalide 
• 641-70-3 3-nitrophthalic acid anhydride 
• 59434-19-4 4-Amino-1(3H)-isobenzofuranon 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 1207454-86-1 ethyl 2-(4-chlorophenyl)-3-(1-methyl-1H-imidazol-2-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207454-84-9 8-(4-chlorophenyl)-9-(1-methyl-1H-imidazol-2-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 

Relevant articles and documents

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.